Tuesday, November 24, 2009, 5:47AM AEST - The Australian Stockmarket opens in 4 hours and 13 minutes.
To create a watchlist or portfolio of shares, Register

Unigene Laboratories Inc. (UGNE.OB)

4:44AM AEST: 0.99 USD  Up 0.01 (1.02%)  
 MORE ON UGNE.OB 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 UNIGENE LABS INC (OTC BB:UGNE.OB) Delayed quote dataEdit
Last Trade:0.99 USD
Trade Time: 4:44AM AEST
Change:Up 0.01 (1.02%)
Prev Close:0.98
Open:0.92
Bid:0.98 x 2500
Ask:1.01 x 500
1y Target Est:2.60
Day's Range:0.92 - 0.99
52wk Range:0.37 - 1.96
Volume:55,350
Avg Vol (3m):159,736
Market Cap:89.85M
P/E (ttm):N/A
EPS (ttm):-0.11
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add UGNE.OB to Portfolio   Download Data

 HEADLINES 
UNIGENE LABORATORIES INC Financials
EDGAR Online Financials (Sat, Nov 14)
UNIGENE LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
EDGAR Online (Tue, Nov 10)
Unigene Announces Financial Results for Third Quarter 2009
Business Wire (Tue, Nov 10)
Q3 2009 Unigene Laboratories, Inc. Earnings Release - After Market Close
CCBN (Mon, Nov 9)
Unigene to Release Third Quarter 2009 Results and Host Conference Call
Business Wire (Wed, Nov 4)
Unigene to Host Conference Call to Discuss Phase III Oral Calcitonin Licensing Agreement with Tarsa Therapeutics
Business Wire (Wed, Oct 21)
UNIGENE LABORATORIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity
EDGAR Online (Tue, Oct 20)
Unigene Licenses Phase III Oral Calcitonin Program to Tarsa Therapeutics
Business Wire (Tue, Oct 20)
U.S. District Court Confirms Validity of Unigene's Fortical® Patent
Business Wire (Wed, Sep 2)
UNIGENE LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
EDGAR Online (Tue, Aug 11)
More Headlines for UGNE.OB...

 ANALYST 
EPS Est (next year) (Dec-08) :N/A
EPS Est (in 2 years) (Dec-09) :N/A
Avg Rec (current)*:3.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of peptides for medical use primarily in the United States.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices